The combination of ds-diam m inedichloroplatinum (II) (DDP, cisplatin) and topoisomerase II inhibitor teniposide (VM-26) has been shown to exert a synergistic effect in the clinical treatm ent of cancer. In this study, the combined effect of D D P and VM-26 on the growth and induction of apoptosis in synchronized murine erythroleukem ia (M EL) cells, treated at the beginning or in the middle of S-phase of cell cycle, was examined. M EL cells, clone F4 N, were synchronized by a double thymidine block leading to accumulation of 70% of cells at the Gj/S boundary. The growth-inhibitory effect of D D P and VM-26 applied alone were stronger in the middle of the S-phase than at the beginning. M orphological analysis showed that the majority of the cells revealed typical signs of apoptosis: nuclei fragmentation and appearance of apoptotic bodies. The com bination of both agents at low concentrations had a synergistic effect on cytotoxicity. A t higher concentrations the effect was additive. The rem ainder of the cells were characterized by unbalanced growth, aberrant mitosis and ap pearance of multinucleated cells. These processes led to delayed cell death. The appearance of aberrant mitosis was more expressed after treatm ent in the middle of the S-phase. It is likely that as a result of the combined action of cisplatin and VM-26, cells become supersensi tive to the ability of topoisomerase II inhibitor to influence mitosis, and this increased sensi tivity may contribute to the observed synergism.
Introduction
The combination of cisplatin (c/s-diamminedichloroplatinum (II), DDP) and topoisomerase II inhibitors has been worldwide successfully used in the treatm ent of lung cancer, malignant lymphoma and testicular cancer. The combined use of D D P with etoposide (VP-16) or teniposide (VM-26) re sulted in a synergistic effect against small cell lung cancer (SCLC) in clinical trials (Evans et al., 1985; Splinter et al., 1996) . The mechanism of this syn ergy is not well understood. A hypothesis was pro posed that synergy between cisplatin and etopo side is caused not by biochemical m odulation at the cellular level but by pharmacokinetic changes at the organism level (Tsai et al., 1989; Kondo et al., 1994) . In vitro experiments with this com bina tion using different SCLC cell lines showed con fusing results, leading in most cases to additive or supra-additive effects (Haller et al., 1993; Minagawa et al., 1997) .
It is known that cisplatin as well as VM-26 are able to induce cell death in a num ber of cell types through apoptosis (Minagawa et al., 1997; Del Bino et al., 1992; Lee et al., 1997) . Moreover, in duction of apoptosis was recently thought to be one of the main mechanisms of the antitumor ef fects of these agents (Barry et al., 1990; Solary et al., 1996; D ubrez et al., 1995) . The cytotoxic effects of cisplatin and VM-26 alone are concentration and cell-cycle dependent: S-phase has been shown to be most sensitive to their action (Gorczyca et al., 1993; Del Bino et al., 1992) . However, the de pendence of the combined action of DDP and VM-26 on the cell cycle is not yet clear.
In the present study, we examined the combined effect of D D P and VM-26 on growth and induc tion of apoptosis in synchronized murine erythro leukemia cells, treated at the beginning or in the middle of the S-phase of the cell cycle.
Materials and Methods

Cell culture and synchronization
Murine erythroleukem ia cells, clone F4 N (virus-transformed erythroid precursor cells) 0939-5075/2001/0900-0892 $ 06.00 © 2001 Verlag der Zeitschrift für Naturforschung, Tübingen • www.znaturforsch.com • D (Dube et al., 1975) , were cultured in Dulbecco's modified Eagle medium (Gibco, G rand Island, NY) (Dulbecco and Freeman, 1959) supplem ented with 10% calf serum, under 5% C 0 2 atm osphere at 37° C, and passed every day at a concentration of 5 x 105 cells/ml. Cells were synchronized at G^ S boundary by a double thymidine block as de scribed by Russev and Boulikas (1992) . Briefly, ex ponentially growing cells were treated twice for 12-h with 2 m M thymidine, with a 9-h interval in thymidine-free medium in between.
To assess cell synchronization, at different times after releasing from the block cells were labeled in duplicate for 15 min at 37° C with 0.004 MBq/ml [3H]thymidine to m onitor precursor incorporation into DNA. Aliquots of cell suspension were pi petted onto Whatman filter paper disks, the acidsoluble radioactivity was extracted with cold trichloroacetic acid (5% ), and the incorporated ac tivity determined by scintillation counting. The average value of quadruplicate determ inations in three independent experiments ±SD was calcu lated.
Incubation with drugs and cytotoxicity evaluation
Synchronized cells (0.5 x 106 cells/ml) were in cubated with cisplatin (prepared according to Spassovska et al. (1981) ) and VM-26 (4'-demethylepipodophyllotoxin-9-(4,6-0-thenylidene -/3 -dglucopyranoside) (teniposide) (Bristol-Mayers, Syracuse, NY) in 24-well or 96-well m icrotiter plates immediately (0 h) or 4 h after releasing from the block. After 72 h of drug treatm ent, the cells were counted hemocytometrically and ana lyzed by fluorescent microscopy. The num ber of dead cells was determined by staining with trypan blue. The mean of triplicate determ inations of three independent experiments ±SD was calcu lated. The 50% inhibitory dose (IC50) was defined as drug concentration that reduced the num ber of living cells by 50%.
Fluorescence microscopy
The cells were fixed with methanol-acetic acid (3:1, v/v), stained with propidium iodide (6 //g/ml, Sigma-Aldrich Chemie GmbH, Deisenhofen, G er many) and viewed using a Leitz orthoplane epifluorescence microscope.
Results and Discussion
In this study, mouse erythorleukem ia cells, clone F4 N, were used in which cisplatin has been shown to readily trigger apoptosis (Vodenicharov et al., 1996) . To study the dependence of the combined action of cisplatin and teniposide on cell cycle phases, the cells were synchronized at the Gi/S boundary by a double thymidine block. To assess the level of cell synchronization, DNA biosynthe sis rate after release from the block was used. The cells showed a typical well-expressed wave of thymidine uptake (Fig. 1) which indicated that over 70% of the cells were synchronized. A maxi mal DNA synthesis rate was observed 4 h after releasing from the block showing that at this time the majority of cells were in the middle of the S-phase.
First, we examined the growth-inhibitory effect of incubation of F4 N cells with cis-DDP or teni poside alone, added at Gi/S boundary or in the middle of S-phase (0 h or 4 h after release from the block, respectively). The cells proved to be m ore sensitive to cisplatin in the middle rather than at the beginning of S-phase (IC50 of 0.40 /u m or 0.6 [am, respectively). Trans-DDP exerted in both cases no effect on cell growth (IC50 more than 80 /u m ). The percentage of dead (trypan blue positive) cells upon drug treatm ent showed that the toxic effect of cisplatin was also most ex pressed in the middle the S-phase (data not shown).
With topoisomerase II inhibitor VM-26, a less expressed dependence of the growth-inhibitory ef fect on cell cycle phases was observed. Thus, trea t ment with this agent at 0 h or 4 h after release from the block resulted in IC50 of 0.04 /u m and 0.02 jUM, respectively. It is worth noting that a cell-cycle dependence of the growth-inhibitory as well as of the toxic effects of VM-26 (Fig. 2) were registered only in a limited interval of relatively low concen trations (< 0.05 piM).
To study the combined action of both drugs, the following cisplatin concentrations were used: 0.25 //m which did practically not influence cell growth when added at 0 h; 0.5 /u m and 1 /u m causing about 30% or 70% growth inhibition, respectively, as well as 2 /um causing 100% growth inhibition (a cytostatic concentration). The dependence of cell growth on VM-26 concentration in the presence of the above amounts of cisplatin is illustrated in Fig. 2 . The drugs were added immediately after re lease from the block (Fig. 2 A ) or at the middle of S-phase (Fig. 2B) . The enhancem ent of the growth-inhibitory effect of VM-26 by cisplatin was more expressed at low concentrations of both drugs and at middle S-phase rather than at S boundary. This was clearly observed at a noneffective concentration of VM-26 (0.0125 /u m ) in combination with growth inhibiting concentrations of cisplatin (0.5 /u m and 1 /u m ) leading to a com plete block of cell growth after treatm ent in the middle of S-phase. A super-additive effect was ob served showing a synergistic action of these drugs. Similar data have been published with Chinese ham ster ovary cells in which the combination of etoposide and D D P resulted in cytotoxicity that was greater than additive at low D D P concentra tions (E der et al., 1990) .
To gain more detailed insight into the cell death process, a morphological analysis of treated F4 N cells was perform ed using the fluorescent dye propidium iodide. Using this m ethod as well as by com et assay, we have previously shown that cis platin caused death of F4 N cells mainly by apoptosis (Kushev et al., 1999) . The apoptotic cells exhibited fragm ented condensed nuclei. A t a later stage, these cells lost their DNA and only cell de bris and few apoptotic bodies (small bright bodies) were observed.
R epresentative results are shown in A fter treatm ent of F4 N cells with 1 / u m DDP, the majority of dead cells showed signs of apoptosis (fragmented nuclei). Following treat m ent at G^S, the viable cells (panel e) became larger and appeared to contain a homogeneously distributed chromatin. Most probably these cells are arrested in G2-phase, as known for the effect of cisplatin (Gorczyca et al., 1993; Vaisman et al., 1997) . A mitotic morphology was not detected. On the contrary, D D P addition in the middle of the S-phase (panel f) resulted in appearance of cells entering mitosis. In a few cells, mitosis proceeded without cytokinesis leading to the appearance of binuclear cells. Some of the cells, however, con tained multiple partial nuclei of different size. Sim ilar effects have been reported for cisplatintreated Chinese ham ster ovary cells (Rodilla, 1993) .
A different pattern of cell morphologies was ob served when cells were treated with 1 /am D D P in the presence of a very low concentration of (Fig. 3, panels g and h) . A t this con centration, VM-26 alone was not cytotoxic exert ing only a weak growth-retardation effect (when added in the middle of S-phase), or having no in fluence on cell growth (when added at G^S boundary); in both cases no changes in cell m or phology were observed. The combined treatm ent did not lead to changes in the m orphology and in the amount of dead cells in comparison with those upon D D P addition only. However, a decrease in the num ber of viable cells and a drastic change of their morphology were observed. Many of the via ble cells were greatly enlarged containing several nuclei (mostly 4 ). Some of them underw ent aber rant/abortive mitosis. This effect was more ex pressed after treatm ent in the middle of the Sphase. Multinucleated cells are not viable, cannot propagate and subsequently die. The morphology of these cells differed from that of apoptotic cells which exhibited nuclei fragmented to small apop totic bodies with a bright highly condensed chro matin.
It is known that topoisomerase II inhibitor VM-26, besides its ability to induce apoptosis via DNA breaks, induces polyploidization by preventing chromatid separation and uncoupling chrom o some dynamics from other cell cycle events (Downes et al., 1991; Clarke et al., 1993) . We ob served the latter effect at concentrations toxic to VM-26. Interesting to note that we were able to register such activity at 10-fold lower VM-26 con centration when combined with cisplatin. There are no published data on the effect of cisplatin on chromosome segregation or mitosis. Most likely as a result of the combined action of cisplatin and VM-26, cells become supersensitive to the ability of topoisomerase II inhibitor to influence mitosis, and this sensitivity could be one of the mecha nisms of synergism.
It seems that the cell suspension that we used is heterogeneous with respect to its sensitivity to cisplatin. Some of the cells became apoptotic after 72 h incubation in the presence of 1 piM cisplatin and contained apoptotic bodies, or became cell ghosts. The surviving cells appeared to exhibit a certain resistance to the induction of apoptosis by cisplatin, revealing at the same time super-sensitiv ity toward the ability of VM-26 to disturb mitosis. In agreem ent with this hypothesis, Minagawa et al. (1997) have recently reported synergism between D D P and VP-16 in KFr cells, a DDP-resistant sub line of the KF epithelial ovarian carcinoma cell line, but not in the parent KF cells.
